Dyne Therapeutics ( $DYN ): Analyzing the -30.5% Pullback After Novartis DM1 Trial News (See the latest news for any ticker on Tickeron.) Dyne Therapeutics shares declined about 30.5% over the 30 days through mid-September 2026, falling from roughly $26.00 to approximately $18.06. The selloff was triggered by Novartis reporting that its Phase 3 HARBOR study of del-desiran failed its primary endpoint in myotonic dystrophy type 1 (DM1), raising read-through concerns for Dyne's competing z-basivarsen program. $RNA $RCKT $BBIO $IDYA $CLDX
published
Dyne Therapeutics ( $DYN ): Analyzing the -30.5% Pullback After Novartis DM1 Trial News (See the latest news for any ticker on Tickeron.) Dyne Therapeutics shares declined about 30.5% over the 30 days through mid-September 2026, falling from roughly $26.00 to
$DYN$RNA$RCKT$BBIO$IDYA$CLDX
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.